Compare GSHD & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | PRCT |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2018 | 2021 |
| Metric | GSHD | PRCT |
|---|---|---|
| Price | $57.31 | $17.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $72.50 | $35.44 |
| AVG Volume (30 Days) | 588.9K | ★ 1.6M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | $308,054,000.00 |
| Revenue This Year | $16.40 | $31.34 |
| Revenue Next Year | $18.53 | $24.52 |
| P/E Ratio | $51.83 | ★ N/A |
| Revenue Growth | 16.15 | ★ 37.22 |
| 52 Week Low | $33.68 | $17.17 |
| 52 Week High | $93.91 | $56.87 |
| Indicator | GSHD | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.36 | 28.06 |
| Support Level | $40.71 | N/A |
| Resistance Level | $77.70 | $29.27 |
| Average True Range (ATR) | 3.95 | 1.12 |
| MACD | -0.21 | -0.15 |
| Stochastic Oscillator | 88.91 | 4.17 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.